However, most anti-PD-1 therapy studies in preclinical GB models focused on the starting time of administration rather than the initial tumour volume [16,17,18], and even for the same preclinical model/cell line, there could be variations in the tumour development rate. This evidence concerns the gene PDCD1 and neoplasm.